{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:48:15Z","timestamp":1790423295108,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.coph.2018.03.015","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T10:47:40Z","timestamp":1526986060000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["ADP-ribosylating enterotoxins as vaccine adjuvants"],"prefix":"10.1016","volume":"41","author":[{"given":"Nils","family":"Lycke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lebrero-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.03.015_bib0640","series-title":"Estimates of Regional and Global Life Expectancy, 1800\u20132001","author":"Riley","year":"2005"},{"key":"10.1016\/j.coph.2018.03.015_bib0645","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1751-7915.2011.00276.x","article-title":"Vaccines for the future: learning from human immunology","volume":"5","author":"De Gregorio","year":"2012","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.coph.2018.03.015_bib0650","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vaccine.2011.11.003","article-title":"New insights in mucosal vaccine development","volume":"30","author":"Pavot","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0655","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","article-title":"New adjuvants for human vaccines","volume":"22","author":"Mbow","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0660","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0665","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2174\/157016210791208695","article-title":"Mucosal adjuvants","volume":"8","author":"Harandi","year":"2010","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.coph.2018.03.015_bib0670","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/08820130903563998","article-title":"Heat-labile enterotoxins as adjuvants or anti-inflammatory agents","volume":"39","author":"Liang","year":"2010","journal-title":"Immunol Invest"},{"key":"10.1016\/j.coph.2018.03.015_bib0675","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijmm.2004.07.002","article-title":"Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin","volume":"294","author":"Fan","year":"2004","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.coph.2018.03.015_bib0680","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/IAI.8.2.208-214.1973","article-title":"Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids","volume":"8","author":"Holmgren","year":"1973","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0685","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1128\/IAI.56.7.1748-1753.1988","article-title":"Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb","volume":"56","author":"Fukuta","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0690","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/IAI.00730-10","article-title":"LT-IIc, a new member of the type II heat-labile enterotoxin family encoded by an Escherichia coli strain obtained from a nonmammalian host","volume":"78","author":"Nawar","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0695","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/glycob\/cws123","article-title":"Ganglioside-binding specificities of E. coli enterotoxin LT-IIc: importance of long-chain fatty acyl ceramide","volume":"23","author":"Berenson","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.coph.2018.03.015_bib0700","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00018-008-7496-5","article-title":"Cholera toxin structure, gene regulation and pathophysiological and immunological aspects","volume":"65","author":"Sanchez","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coph.2018.03.015_bib0705","doi-asserted-by":"crossref","first-page":"12010","DOI":"10.1016\/S0021-9258(19)50301-5","article-title":"Brefeldin a blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action","volume":"268","author":"Orlandi","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.03.015_bib0710","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1083\/jcb.133.4.777","article-title":"Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in vero cells","volume":"133","author":"Majoul","year":"1996","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coph.2018.03.015_bib0715","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0092-8674(01)00289-6","article-title":"Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin","volume":"104","author":"Tsai","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.03.015_bib0720","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1083\/jcb.148.6.1203","article-title":"Cholera toxin is exported from microsomes by the Sec61p complex","volume":"148","author":"Schmitz","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coph.2018.03.015_bib0725","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/IAI.70.11.6172-6179.2002","article-title":"Inhibition of endoplasmic reticulum-associated degradation in CHO cells resistant to cholera toxin, pseudomonas aeruginosa exotoxin A, and ricin","volume":"70","author":"Teter","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0730","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/embo-reports\/kvf239","article-title":"Role of ubiquitination in retro-translocation of cholera toxin and escape of cytosolic degradation","volume":"3","author":"Rodighiero","year":"2002","journal-title":"EMBO Rep"},{"key":"10.1016\/j.coph.2018.03.015_bib0735","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/S0021-9258(20)82130-9","article-title":"Purification of a protein cofactor required for ADP-ribosylation of the stimulatory regulatory component of adenylate cyclase by cholera toxin","volume":"259","author":"Kahn","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.03.015_bib0740","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1126\/science.1113398","article-title":"Structural basis for the activation of cholera toxin by human ARF6-GTP","volume":"309","author":"O\u2019Neal","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coph.2018.03.015_sbref0745","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/mmi.12807","article-title":"ADP-ribosylation factor 6 acts as an allosteric activator for the folded but not disordered cholera toxin A1 polypeptide","volume":"94","author":"Banerjee","year":"2014","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.coph.2018.03.015_bib0750","doi-asserted-by":"crossref","first-page":"12148","DOI":"10.1016\/S0021-9258(18)33691-3","article-title":"Mechanism of action of cholera toxin on intact cells. Generation of A1 peptide and activation of adenylate cyclase","volume":"257","author":"Kassis","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.03.015_bib0755","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1016\/S0021-9258(20)82131-0","article-title":"ADP-ribosylation of Gs promotes the dissociation of its alpha and beta subunits","volume":"259","author":"Kahn","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.03.015_bib0760","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/toxins7030919","article-title":"A mutational analysis of residues in cholera toxin A1 necessary for interaction with its substrate, the stimulatory G protein gsalpha","volume":"7","author":"Jobling","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2018.03.015_bib0765","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","article-title":"Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel","volume":"66","author":"Cheng","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.03.015_bib0770","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1126\/science.7524148","article-title":"Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model","volume":"266","author":"Gabriel","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.coph.2018.03.015_bib0775","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(99)70063-6","article-title":"Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults","volume":"116","author":"Michetti","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.03.015_bib0780","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1128\/IAI.70.4.1874-1880.2002","article-title":"Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously","volume":"70","author":"Guerena-Burgueno","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0785","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2007.01.043","article-title":"Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study","volume":"25","author":"McKenzie","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0790","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)60839-9","article-title":"Use of a patch containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial","volume":"371","author":"Frech","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.03.015_bib0795","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.vaccine.2008.02.070","article-title":"Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch","volume":"26","author":"Frerichs","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0800","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.03.015_sbref0805","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/mi.2014.111","article-title":"Cholera toxin adjuvant promotes a balanced Th1\/Th2\/Th17 response independently of IL-12 and IL-17 by acting on Gsalpha in CD11b(+) DCs","volume":"8","author":"Mattsson","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0810","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1084\/jem.20080912","article-title":"Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function","volume":"206","author":"la Sala","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2018.03.015_bib0815","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/eji.1830230914","article-title":"Cholera toxin adjuvant greatly promotes antigen priming of T cells","volume":"23","author":"Hornquist","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0820","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/173.3.627","article-title":"Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin","volume":"173","author":"Takahashi","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.03.015_bib0825","doi-asserted-by":"crossref","first-page":"11010","DOI":"10.1128\/JVI.75.22.11010-11016.2001","article-title":"Rotavirus 2\/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1\/Th2-like immune response","volume":"75","author":"Fromantin","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coph.2018.03.015_bib0830","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/IAI.71.4.1740-1747.2003","article-title":"Cholera toxin and its b subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development","volume":"71","author":"Eriksson","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0835","doi-asserted-by":"crossref","first-page":"e5190","DOI":"10.1371\/journal.pone.0005190","article-title":"Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens","volume":"4","author":"Lee","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.03.015_bib0840","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/IAI.00536-10","article-title":"Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach","volume":"78","author":"Raghavan","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0845","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/eji.201040997","article-title":"Intradermal immunization in the ear with cholera toxin and its non-toxic beta subunit promotes efficient Th1 and Th17 differentiation dependent on migrating DCs","volume":"41","author":"Meza-Sanchez","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0850","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.vaccine.2010.11.020","article-title":"LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb","volume":"29","author":"Nawar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0855","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/(SICI)1521-4141(199906)29:06<1774::AID-IMMU1774>3.0.CO;2-1","article-title":"The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action","volume":"29","author":"Grdic","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0860","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.4049\/jimmunol.169.12.6977","article-title":"Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells","volume":"169","author":"Akhiani","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0865","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1073\/pnas.1002348107","article-title":"Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax","volume":"107","author":"Datta","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2018.03.015_bib0870","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/mi.2010.16","article-title":"Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant","volume":"3","author":"Sjoblom-Hallen","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0875","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2010.10.006","article-title":"Signal transduction pathways and transcriptional regulation in Th17 cell differentiation","volume":"21","author":"Hirahara","year":"2010","journal-title":"Cytok Growth Factor Rev"},{"key":"10.1016\/j.coph.2018.03.015_sbref0880","doi-asserted-by":"crossref","first-page":"372-379","DOI":"10.1038\/ni.2552","article-title":"Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses","volume":"14","author":"Hirota","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0885","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.4049\/jimmunol.146.9.2908","article-title":"Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro","volume":"146","author":"Bromander","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0890","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/1521-4141(200101)31:1<64::AID-IMMU64>3.0.CO;2-P","article-title":"Effects of cholera toxin on macrophage production of co-stimulatory cytokines","volume":"31","author":"Cong","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0895","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.4049\/jimmunol.1003789","article-title":"Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production","volume":"186","author":"Brereton","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0900","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","article-title":"Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling","volume":"194","author":"Larena","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_sbref0905","doi-asserted-by":"crossref","first-page":"e0178114","DOI":"10.1371\/journal.pone.0178114","article-title":"Low doses of cholera toxin and its mediator cAMP induce CTLA-2 secretion by dendritic cells to enhance regulatory T cell conversion","volume":"12","author":"Silva-Vilches","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.03.015_bib0910","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.4049\/jimmunol.171.5.2384","article-title":"Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation","volume":"171","author":"Lavelle","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0915","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MOG.0b013e3283365279","article-title":"STAT3 and its activators in intestinal defense and mucosal homeostasis","volume":"26","author":"Hruz","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.coph.2018.03.015_bib0920","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.4049\/jimmunol.163.7.3668","article-title":"Modulating dendritic cells to optimize mucosal immunization protocols","volume":"163","author":"Williamson","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0925","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y","article-title":"Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming","volume":"30","author":"Gagliardi","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0930","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.4049\/jimmunol.175.8.5192","article-title":"Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin","volume":"175","author":"Grdic","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0935","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.4049\/jimmunol.0803568","article-title":"CCR7-CCL19\/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination","volume":"182","author":"Song","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib0940","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1128\/IAI.73.10.6892-6902.2005","article-title":"Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract","volume":"73","author":"van Ginkel","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0945","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1128\/IAI.65.7.2821-2828.1997","article-title":"Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin","volume":"65","author":"Douce","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0950","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.185.7.1203","article-title":"Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity","volume":"185","author":"Yamamoto","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2018.03.015_bib0955","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/S0264-410X(00)00058-X","article-title":"Effective mucosal immunization against respiratory syncytial virus using purified f protein and a genetically detoxified cholera holotoxin, CT-E29H","volume":"18","author":"Tebbey","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0960","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/S0264-410X(02)00351-1","article-title":"Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K)","volume":"20","author":"Watanabe","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0965","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1084\/jem.187.7.1123","article-title":"Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity","volume":"187","author":"Giuliani","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2018.03.015_bib0970","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1046\/j.1365-2567.1999.00817.x","article-title":"Mucosal immunogenicity and adjuvant activity of the recombinant a subunit of the Escherichia coli heat-labile enterotoxin","volume":"97","author":"De Haan","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.coph.2018.03.015_bib0975","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0264-410X(99)00168-1","article-title":"The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)","volume":"18","author":"Cheng","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0980","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1438-4221(00)80064-8","article-title":"LTK63 and LTR72, two mucosal adjuvants ready for clinical trials","volume":"290","author":"Pizza","year":"2000","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.coph.2018.03.015_bib0985","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/IAI.69.3.1605-1612.2001","article-title":"Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii","volume":"69","author":"Bonenfant","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib0990","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/S0264-410X(02)00215-3","article-title":"Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity","volume":"20","author":"Chen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib0995","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1016\/j.vaccine.2007.09.004","article-title":"Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats","volume":"25","author":"Tempesta","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1000","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.vaccine.2007.01.036","article-title":"Enhancement of intranasal vaccination with recombinant chain a ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72","volume":"25","author":"Kende","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1005","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1016\/j.vaccine.2008.05.083","article-title":"Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006","volume":"26","author":"Brynjolfsson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1010","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.vaccine.2008.12.010","article-title":"Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge","volume":"27","author":"Romero","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1015","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1128\/CVI.05273-11","article-title":"Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine","volume":"18","author":"Barrette","year":"2011","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1020","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.vaccine.2013.02.060","article-title":"An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine","volume":"31","author":"Alejo","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1025","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1128\/JVI.80.10.4962-4970.2006","article-title":"Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers","volume":"80","author":"Stephenson","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coph.2018.03.015_bib1030","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.03.015_bib1035","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.coph.2018.03.015_sbref1040","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.vaccine.2016.03.002","article-title":"Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae","volume":"34","author":"Lebens","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1045","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/IAI.01407-12","article-title":"A double mutant heat-labile toxin from Escherichia coli, LT(R192G\/l211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection","volume":"81","author":"Sjokvist Ottsjo","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1055","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1128\/IAI.69.6.3581-3590.2001","article-title":"Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection","volume":"69","author":"Kotloff","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.vaccine.2009.10.147","article-title":"Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin","volume":"28","author":"Summerton","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_sbref1065","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-0463.2000.d01-42.x","article-title":"Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and\/or of co-administration with free toxin as adjuvant","volume":"108","author":"Rask","year":"2000","journal-title":"APMIS: Acta Pathol Microbiol Immunol Scand"},{"key":"10.1016\/j.coph.2018.03.015_bib1075","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.176.5.2749","article-title":"Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin","volume":"176","author":"Luci","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1080","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1007\/s00253-013-5408-6","article-title":"Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB\/c mice model","volume":"98","author":"Guo","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"issue":"Pt 2","key":"10.1016\/j.coph.2018.03.015_bib1085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1099\/mic.0.049932-0","article-title":"Construction of bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli","volume":"158","author":"Ma","year":"2012","journal-title":"Microbiology (Reading, England)"},{"key":"10.1016\/j.coph.2018.03.015_bib1090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.vetmic.2014.07.009","article-title":"Local and systemic immune responses induced by a recombinant chimeric protein containing mycoplasma hyopneumoniae antigens fused to the B subunit of Escherichia coli heat-labile enterotoxin LTB","volume":"173","author":"Marchioro","year":"2014","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.coph.2018.03.015_bib1095","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00436-015-4316-3","article-title":"Protective immunity against naegleria fowleri infection on mice immunized with the rNfa1 protein using mucosal adjuvants","volume":"114","author":"Lee","year":"2015","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.03.015_bib1100","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.000543","article-title":"Construction of an inactivated typhoid vaccine candidate expressing Escherichia coli heat-labile enterotoxin B subunit and evaluation of its immunogenicity in a murine model","author":"Kim","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.coph.2018.03.015_bib1105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00063","article-title":"Sublingual priming with a hiv gp41-based subunit vaccine elicits mucosal antibodies and persistent B memory responses in non-human primates","volume":"8","author":"Bekri","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1110","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1128\/IAI.69.6.4125-4128.2001","article-title":"Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans","volume":"69","author":"Jertborn","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1115","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1128\/IAI.69.12.7481-7486.2001","article-title":"Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans","volume":"69","author":"Johansson","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.vaccine.2016.11.055","article-title":"Kinetics of antibody-secreting cell and fecal iga responses after oral cholera vaccination in different age groups in a cholera endemic country","volume":"35","author":"Akhtar","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2009.02321.x","article-title":"Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit","volume":"71","author":"Sun","year":"2010","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/vaccines3030579","article-title":"Cholera toxin subunit B as adjuvant \u2013 an accelerator in protective immunity and a break in autoimmunity","volume":"3","author":"Stratmann","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.coph.2018.03.015_bib1135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2249.2004.02520.x","article-title":"Oral tolerization with peptide 336\u2013351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease","volume":"137","author":"Stanford","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2009.04185.x","article-title":"Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active crohn's disease","volume":"31","author":"Stal","year":"2010","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2018.03.015_sbref1145","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/eji.201242867","article-title":"Direct interaction between cholera toxin and dendritic cells is required for oral adjuvant activity","volume":"43","author":"Gustafsson","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_sbref1150","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.vaccine.2014.02.056","article-title":"As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity- and IL-6-dependent manner","volume":"32","author":"Wan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1155","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1440-1711.1998.00750.x","article-title":"A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit","volume":"76","author":"Agren","year":"1998","journal-title":"Immunol Cell Biol"},{"issue":"Pt 12","key":"10.1016\/j.coph.2018.03.015_bib1165","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1099\/vir.0.2008\/005470-0","article-title":"CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization","volume":"89","author":"Sundling","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coph.2018.03.015_bib1170","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1175","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.4049\/jimmunol.162.4.2432","article-title":"Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity","volume":"162","author":"Agren","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1180","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.164.12.6276","article-title":"The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects","volume":"164","author":"Agren","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1185","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.4049\/jimmunol.1101107","article-title":"Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant","volume":"187","author":"Mattsson","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1190","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4049\/jimmunol.1002881","article-title":"A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development","volume":"186","author":"Bemark","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_sbref1195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/mi.2017.14","article-title":"M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection","volume":"11","author":"Eliasson","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3083.2005.01713.x","article-title":"The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization","volume":"63","author":"Akhiani","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1205","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1016\/j.vaccine.2007.05.065","article-title":"Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge","volume":"25","author":"McNeal","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jri.2009.04.002","article-title":"CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa","volume":"81","author":"Cunningham","year":"2009","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1215","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.015_bib1220","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/art.24566","article-title":"Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis","volume":"60","author":"Hasselberg","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2018.03.015_sbref1225","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/pbi.12479","article-title":"Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis","volume":"14","author":"Hansson","year":"2016","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.coph.2018.03.015_bib1230","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/sji.12157","article-title":"Administration of sulfatide to ameliorate type I diabetes in non-obese diabetic mice","volume":"79","author":"Rhost","year":"2014","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01133","article-title":"A novel approach to reinstating tolerance in experimental autoimmune myasthenia gravis using a targeted fusion protein, mCTA1-T146","volume":"8","author":"Consonni","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cei.12487","article-title":"Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10\u201360 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model","volume":"180","author":"Kap","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1245","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.4049\/jimmunol.0901445","article-title":"ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization","volume":"184","author":"Hasselberg","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1250","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/IAI.65.12.4943-4950.1997","article-title":"Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin","volume":"65","author":"Guidry","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1255","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2567.1998.00535.x","article-title":"Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit","volume":"94","author":"de Haan","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.coph.2018.03.015_bib1260","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.177.2.1197","article-title":"Gm1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant","volume":"177","author":"Zoeteweij","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.015_bib1265","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/IAI.00181-12","article-title":"The a subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes igG2a, IgA, and Th17 responses to vaccine antigens","volume":"80","author":"Norton","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2018.03.015_bib1270","doi-asserted-by":"crossref","DOI":"10.1186\/1756-3305-6-63","article-title":"Compound DNA vaccine encoding SAG1\/SAG3 with A2\/B subunit of cholera toxin as a genetic adjuvant protects BALB\/c mice against Toxoplasma gondii","volume":"6","author":"Cong","year":"2013","journal-title":"Parasit Vectors"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217302151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217302151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:19:11Z","timestamp":1693667951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217302151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":127,"alternative-id":["S1471489217302151"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.015","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADP-ribosylating enterotoxins as vaccine adjuvants","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}